WEBULL
News
XOMA
23.62
+1.50%
0.35
XOMA Royalty: Preferreds Still Offer Compelling Income Despite Call Risk
Seeking Alpha · 1d ago
*News On Generation Bio Inc. (GBIO) Now Under XOMA
Dow Jones · 2d ago
XOMA Royalty Completes Generation Bio Acquisition and Merger
TipRanks · 2d ago
XOMA Royalty Completes Acquisition of Generation Bio for $4.29 Per Share
Reuters · 3d ago
XOMA Royalty übernimmt Generation Bio für 4,29 Dollar je Aktie
Reuters · 3d ago
*XOMA Royalty Announces Closing Of Tender Offer And Completed Acquisition Of Generation Bio, Inc. >XOMA
Dow Jones · 3d ago
Weekly Report: what happened at XOMA last week (0202-0206)?
Weekly Report · 3d ago
XOMA Royalty Corporation veröffentlicht ergänzten Bericht zu LAVA-Legacy-Assets
Reuters · 02/02 21:34
XOMA Royalty Corporation Issues Amendment to Report on LAVA Legacy Assets
Reuters · 02/02 21:34
Weekly Report: what happened at XOMA last week (0126-0130)?
Weekly Report · 02/02 09:40
Weekly Report: what happened at XOMA last week (0119-0123)?
Weekly Report · 01/26 09:41
Weekly Report: what happened at XOMA last week (0112-0116)?
Weekly Report · 01/19 09:44
XOMA Royalty Appoints New Chief Financial Officer
TipRanks · 01/15 21:48
XOMA Royalty Appoints Jeffrey Trigilio CFO, Effective Jan. 12, Succeeding Thomas Burns
Benzinga · 01/15 21:28
XOMA Royalty Corporation Files Initial Beneficial Ownership Statement for CFO Jeffrey Trigilio
Reuters · 01/14 21:30
XOMA Royalty CFO Thomas Burns To Resign, Jeffrey Trigilio To Be New CFO
NASDAQ · 01/12 13:27
Xoma announces CFO Burns to step down, Trigilio to succeed
TipRanks · 01/12 12:56
XOMA Royalty Names Jeffrey Trigilio Finance Chief as Thomas Burns Departs
Dow Jones · 01/12 12:50
XOMA Highlights Royalty Growth Strategy in Updated Presentation
TipRanks · 01/12 12:39
XOMA ROYALTY CORP - APPOINTS JEFFREY TRIGILIO AS CFO
Reuters · 01/12 12:30
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.